Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)

NCT03193437 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT03193437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03193437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Terminated
Start date
April 3, 2018
Completion date
January 31, 2022
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced thymic epithelial tumor, thymoma